Friday, July 10, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “antiplatelet” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 8
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 8 pipeline programs matching "antiplatelet" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

8 results for “antiplatelet” Back to intelligence hub

Search results

  1. CAMER5UA

    United Therapeutics Europe Ltd

    Cervical Artery Dissection

    phase 3 small molecule completed

    1 trial
  2. Start antiplatelet monotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Intracerebral Hemorrhage

    phase 3 small molecule completed

    1 trial
  3. 22375

    Bayer AG

    Prevention of ischemic stroke in patients after an acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack in combination with antiplatelet therapy

    phase 1 other active

    1 trial
  4. Combination of antiplatelet drugs and anticoagulants for at least one month

    The First People's Hospital of Lianyungang

    Acute Myocardial Infarction

    approved small molecule active

    1 trial
  5. De-escalated Dual Antiplatelet Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary Artery Disease

    approved small molecule completed

    1 trial
  6. ICI22/00054

    The George Institute

    patients who are requested a colonoscopy for any indication and are under antiplatelet treatment (except ASA) or anticoagulant treatment

    approved small molecule active

    1 trial
  7. Adjustment of Antiplatelet Drugs

    The First People's Hospital of Lianyungang

    Intracranial Aneurysm

    small molecule completed

    1 trial
  8. AntiPlatelet therapy

    The First People's Hospital of Lianyungang

    Coronary Artery Disease

    small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.